Volume 1 | Issue 1 | DOI: https://doi.org/10.33696/cardiology.1.005
A View on the Contribution of Hedgehog Signalling to Ventricular Septal Development
- 1Institute for Animal Developmental and Molecular Biology, Heinrich Heine University, 40225 Düsseldorf, Germany
Christoph Gerhardt, Christoph.Gerhardt@hhu.de
Received Date: June 10, 2020
Accepted Date: August 26, 2020
Gerhardt C. A View on the Contribution of Hedgehog Signalling to Ventricular Septal Development. J Clin Cardiol. 2020; 1(1):40-42.
Copyright: © 2020 Gerhardt C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A New Window onto the Pacemaker of the Heart, the Sinus Node, Provided by Quantitative Proteomics and Single- Nucleus Transcriptomics
Hypothesis-driven research has dominated biomedical science for at least the past century. There are many papers and grant applications that will have been rejected because they are not hypothesis-driven. For example, Haufe reports that the NIH guidelines for RO1 grants states that “A strong grant application is driven by a strong, solid hypothesis with clear research objectives”.
Bromodomain and Extra-Terminal Family Protein Inhibitors: A Potentially New Therapy for Heart Disease
Bromodomain-containing protein 4 (BRD4) is a member of the mammalian bromo- and extra-terminal domain (BET) protein family, which also comprises BRD2, BRD3, and testis-specific BRDt.
It is well established that lateral elbow pain and dysfunction is a common pathology in general and sport populations [1-3]. Lateral elbow pain has been termed tennis elbow, epicondylitis, elbow tendinosis, elbow tendinopathy, but currently, the term lateral epicondylalgia (LE) encompasses the spectrum of degeneration and
Estimated Plasma Volume Status (ePVS) for Diastolic Heart Failure in the Intensive Care Unit: A Retrospective Cohort Study
Diastolic heart failure (DHF) is also be regarded as heart failure with preserved ejection fraction (HFpEF), is estimated to occur in 40 to 50% of patients with HF. More than 70% of HF patients over the age of 65 had HFpEF, and the incidence and prevalence of HFpEF has been increased by 10% every 10 years in comparison to HF with reduced ejection fraction (HFrEF), and this gap is expected to widen in the coming years.
Heart failure affects 1-2% of the adult population in developed countries and the lifetime risk of a heart failure diagnosis is 20%. Patients with heart failure have markedly reduced life expectancy, physical capacity and quality of life. One-year all-cause mortality rates for heart failure patients range between 7 and 17% and the yearly hospitalization rate can be as high as 44%.